Anzeige
Mehr »
Freitag, 29.08.2025 - Börsentäglich über 12.000 News
Neuer Uran-Boom: Die Warren Buffett-Chance im heißesten Wachstumsmarkt der kommenden Dekade!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1XFUX | ISIN: IL0011313900 | Ticker-Symbol: GPH
Lang & Schwarz
28.08.25 | 07:00
6,500 Euro
-100,00 % -6,500
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GALMED PHARMACEUTICALS LTD Chart 1 Jahr
5-Tage-Chart
GALMED PHARMACEUTICALS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
6,4006,60028.08.

Aktuelle News zur GALMED Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoGalmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update62TEL AVIV, Israel, Aug. 28, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company...
► Artikel lesen
MoGalmed to invest up to $10M in digital assets as part of new strategy13
MoGalmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer1
18.08.Galmed files to sell 7.5M shares of common stock for holders2
18.08.Galmed Pharmaceuticals Ltd. - F-1, Registration statement for certain foreign private issuers3
GALMED Aktie jetzt für 0€ handeln
15.08.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer1
24.07.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer3
22.05.Galmed GAAP EPS of -$0.62 beats by $0.276
22.05.Galmed Pharmaceuticals Ltd.: Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update560TEL AVIV, Israel, May 22, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company...
► Artikel lesen
22.05.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer1
13.05.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer1
13.05.Galmed Pharmaceuticals Ltd.: Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models162Aramchol, an SCD1 inhibitor, significantly attenuates and prevents biliary fibrosis in mouse models of primary sclerosing cholangitis (PSC) Aramchol treatment...
► Artikel lesen
06.05.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer6
06.05.Galmed Pharmaceuticals Ltd.: Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models785Results from studies at Virginia Commonwealth University (VCU) show that an Aramchol and Bayer's Regorafenib drug combination significantly reduced hepatic tumor...
► Artikel lesen
02.05.Galmed, Entomus Partner to Introduce Sublingual Semaglutide2
28.04.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer3
17.04.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer2
15.04.Galmed Pharmaceuticals Ltd.: Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor174Analysis of blood samples from patients treated with Aramchol in ARMOR (Ph3 MASH Study) provides new and important insights into the biochemical and physiological...
► Artikel lesen
10.04.Galmed Reports Positive Part 1 Results From AM-001 Study Of Aramchol Meglumine1
10.04.Galmed Pharmaceuticals Ltd. - 6-K, Report of foreign issuer1
Weiter >>
27 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1